7-Chloro-5-methyl-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3-phenylpyridazino[4,5-b]indol-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-Chloro-5-methyl-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3-phenylpyridazino[4,5-b]indol-4-one
• 化学式: C₂₄H₂₄ClN₅O₂
• 分子量: 449.9
• InChiKey: OKDGMOASNOUQBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug
  申请人：Pharmacia Corporation

  公开号：US20040063751A1

  公开（公告）日：2004-04-01

  A method of treating, preventing, or inhibiting ALS, in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes an ALS treatment, inhibition or prevention effective amount.

  一种治疗、预防或抑制 ALS 的方法。该方法包括向受试者施用一种或多种环氧化酶-2 选择性抑制剂或异构体或其药学上可接受的盐、酯或原药，并与一种或多种第二种药物结合使用、其中，环氧合酶-2 选择性抑制剂或异构体或其药学上可接受的盐、酯或原药的量与第二种药物的量结合构成 ALS 治疗、抑制或预防有效量。
• AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1539169A2

  公开（公告）日：2005-06-15
• [EN] COMBINATION THERAPY FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) AND A SECOND DEUG<br/>[FR] COMBINAISON DE THERAPIES PERMETTANT DE TRAITER LA SCLEROSE AMYOTROPHIQUE LATERALE (ALS) A L'AIDE D'INHIBITEUR(S) DE LA CYCLOOXYGENASE-2 (COX 2) ET D'UN SECOND MEDICAMENT
  申请人：PHARMACIA CORP

  公开号：WO2003101380A2

  公开（公告）日：2003-12-11

  A method of treating, preventing, or inhibiting ALS, in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes an ALS treatment, inhibition or prevention effective amount.